Brazilian brown propolis elicits antileishmanial effect against promastigote and amastigote forms of Leishmania amazonensis

• Published in: Natural product research Vol. 28; no. 5; pp. 340 - 343
• Main Authors: Santana, Lorena C.L.R., Carneiro, Sabrina Maria P., Caland-Neto, Laurentino B., Arcanjo, Daniel D.R., Moita-Neto, José M., Citó, Antônia M.G.L., Carvalho, Fernando Aécio A.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 04-03-2014
• Subjects: Animals; antiparasitic activity; Antiprotozoal Agents - chemistry; Antiprotozoal Agents - isolation & purification; Antiprotozoal Agents - pharmacology; Brazil; brown propolis; cytotoxicity; Gas Chromatography-Mass Spectrometry; Inhibitory Concentration 50; Leishmania - drug effects; leishmaniasis; Leishmaniasis - drug therapy; Macrophages, Peritoneal - drug effects; propolis; Propolis - chemistry; Propolis - pharmacology; Brazil
• ISSN: 1478-6419; 1478-6427
• DOI: 10.1080/14786419.2013.856904

Propolis is a complex matrix of chemical constituents extracted from plants and produced by bees which is used in folk medicine due to its several pharmacological properties. Its chemical composition varies according to the region where it is produced. This work has studied the antileishmanial activity and cytotoxicity of brown propolis (BP) originating from the semi-arid region of Piauí, Brazil. The BP showed significant inhibition of the Leishmania amazonensis promastigotes growth as well as being effective in reducing infection of murine macrophages and the number of internalised amastigotes in these cells. The dichloromethane fraction was the most active and showed the best selectivity index. The studied samples presented good activity and the fractioning improved the antileishmanial activity without an increase in the cytotoxicity against mammalian cells. Therefore, BP is a potential source for development of apitherapeutic products for the treatment of leishmaniasis.